Microfluidic-Based Manufacture of siRNA-Lipid Nanoparticles for Therapeutic Applications


Authors: C. Walsh, K. Ou, N.M. Belliveau, T.J. Leaver, A.W. Wild, J. Huft, P.J. Lin, S. Chen, A.K. Leung, J.B. Lee, C.L. Hansen, R.J. Taylor, E.C. Ramsay and P.R Cullis

Journal: Methods in Molecular Biology

DOI: 10.1007/978-1-4939-0363-4_6

Publication - Abstract

February 03, 2014

siRNA Nucleic Acid Lipid Nanoparticles Genetic Medicine

Abstract:

A simple, efficient, and scalable manufacturing technique is required for developing siRNA-lipid nanoparticles (siRNA-LNP) for therapeutic applications. In this chapter we describe a novel microfluidic-based manufacturing process for the rapid manufacture of siRNA-LNP, together with protocols for characterizing the size, polydispersity, RNA encapsulation efficiency, RNA concentration, and total lipid concentration of the resultant nanoparticles.


limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

May 29, 2020
Scientific Reports

Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines

E.M. Mucker, P.P. Karmali, J. Vega, S.A. Kwilas, H. Wu, M. Joselyn, J. Ballantyne, D. Sampey, R. Mukthavaram, E. Sullivan, P. Chivukula and J.W. Hooper

DNA Nucleic Acid Lipid Nanoparticles Vaccines
The use of nucleic acid as a drug substance for vaccines and other gene-based medicines continues to evolve. Here, we have used a technology originally developed for mRNA in vivo delivery to enhance the immunogenicity of DNA vaccines. We demonstrate that neutralizing antibodies p...
Read More


Publication - Abstract

Jun 10, 2015
ACS Nano

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

S. Ramishetti, R. Kedmi, M. Goldsmith, F. Leonard, A.G. Sprague, B. Godin, M. Gozin, P.R. Cullis, D.M. Dykxhoorn and D. Peer

Hematology Targeted Drug Delivery siRNA

Modulating T cell function by down-regulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune-related disorders including cancer, inflammation, autoimmunity,...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up